Eli Lilly & Co

LLY

Equity

ISIN null / Valor 947556

New York Stock Exchange, Inc (2026-11-02)

USD 1,406.15-0.80%

Eli Lilly & Co
UMushroom community rating:

4.20 93 votes No rating yet

NegativeNeutralPositive

About company

Eli Lilly & Co, headquartered in Indianapolis, is a global pharmaceutical company with a significant presence in the healthcare sector. Known for its research, development, and commercialization of pharmaceutical products, Eli Lilly focuses on a wide range of therapeutic areas including but not limited to oncology, diabetes, neurodegeneration, and immunology. The company has recently announced results from a pioneering study of lebrikizumab, a treatment specifically designed for individuals with skin of color suffering from moderate-to-severe atopic dermatitis, also known as eczema. This highlights Eli Lilly's commitment to addressing diverse medical needs and expanding its portfolio to include treatments tailored for specific demographic groups. The company's efforts in innovation and targeted research underscore its role in advancing medical treatments and improving patient outcomes across various disease states.

Summarized from source with an LLMView SourceSector: Technology

Yasir Ahmed

UK, 02 Nov 2026

Weight loss drugs driving huge growth, strong run and still going

Aakarsh Deepak Boswan

UK, 02 Nov 2026

Beat Q3 estimates and raised full-year guidance on strong tirzepatide (Mounjaro, Zepbound) demand, sending the stock to a new record. A clear leader in obesity drugs, though at a $1tn+ valuation it is priced for continued growth, so any slowdown would hurt.